Mazdutide (10mg)

Mazdutide (IBI362) is a once-weekly injectable dual agonist targeting both GLP-1 (glucagon-like peptide-1) and glucagon (GCGR) receptors, developed by Innovent Biologics. This dual-receptor mechanism distinguishes it from pure GLP-1 agonists by adding glucagon receptor activation, which increases energy expenditure and enhances hepatic fat mobilization beyond appetite suppression alone.

The GLP-1 component reduces appetite, slows gastric emptying, and improves insulin sensitivity — mechanisms shared with semaglutide. The GCGR component provides a distinct metabolic advantage by increasing basal metabolic rate, promoting hepatic gluconeogenesis suppression, and mobilizing visceral fat through cAMP-mediated lipolysis. This dual action creates synergistic weight loss and metabolic benefits that address both energy intake (GLP-1) and energy expenditure (GCGR).

This 10 mg vial is designed for maintenance dosing in established research protocols where weekly doses of 3–4.5 mg have been titrated and tolerability confirmed. It provides a larger supply per vial, making it cost-effective for longer-duration research programs. Phase 2 and 3 clinical trials have demonstrated significant weight loss (up to ~19%) and cardiometabolic improvements in participants with overweight and obesity.